10-K: iRhythm Holdings Reports Strong Revenue Growth Amid Legal Scrutiny

iRhythm Holdings, Inc. reported a 26% increase in revenue and a significantly reduced net loss for 2025, while navigating multiple ongoing legal and regulatory challenges.

Summary

• Revenue increased by 26% to $747.1 million in 2025, up from $591.8 million in 2024, driven by increased demand for iRhythm Services.
• Net loss decreased significantly to $44.6 million in 2025 from $113.3 million in 2024.
• Gross profit rose by 29% to $527.3 million in 2025, with the gross margin improving from 69% in 2024 to 71% in 2025.
• Adjusted EBITDA turned positive, reaching $68.9 million in 2025, compared to a negative $7.7 million in 2024.
• The company transitioned to a corporate holding company structure on January 12, 2026, with iRhythm Holdings, Inc. becoming the parent company of iRhythm Technologies, Inc.
• Medicare program accounted for approximately 24% of total revenue in 2025.
• The company is actively involved in several legal proceedings, including a securities class action lawsuit, patent infringement lawsuits by Welch Allyn and BardyDx, and Department of Justice (DOJ) investigations.
• A Technology License Agreement with BioIntelliSense, Inc. (BioIS) was entered into in August 2024, involving a $15.0 million upfront fee and $40.0 million in convertible promissory notes, with $10.0 million in Milestone Notes expected to be cancelled in 2025 due to a regulatory milestone achievement.
• The Development Collaboration Agreement with Verily Life Sciences LLC was mutually terminated in August 2025, resulting in $11.0 million in milestone payments to Verily.
• Impairment charges of $4.5 million were recorded in 2025, primarily for capitalized internal-use software related to the Zio Watch, which will not be commercially launched.
• The maximum aggregate number of shares that may be issued under the 2016 Equity Incentive Plan as of the Amendment Date (November 7, 2024) is 5,169,736 shares, plus certain lapsed awards from the 2006 Stock Plan.
• The 2016 Employee Stock Purchase Plan (ESPP) allows eligible employees to purchase shares at a discount, with approximately 1.9 million shares remaining available for issuance as of December 31, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, highlighting strong revenue growth and significant improvement in key profitability metrics like Adjusted EBITDA and gross margin, despite ongoing legal and regulatory challenges. The strategic initiatives and market leadership position the company for continued growth.

Positives

• Strong revenue growth of 26% year-over-year, reaching $747.1 million in 2025, driven by increased demand for iRhythm Services.
• Significant improvement in profitability, with net loss decreasing by 61% to $44.6 million in 2025 and Adjusted EBITDA turning positive at $68.9 million.
• Gross margin improved from 69% in 2024 to 71% in 2025, indicating better cost management or pricing power.
• Successful FDA 510(k) clearances for Zio AT design updates in October 2024, demonstrating continued product development and regulatory compliance.
• Strategic technology license agreement with BioIntelliSense for next-generation products and potential expansion into adjacent clinical areas like sleep apnea.
• Achievement of a regulatory milestone with BioIS, leading to the cancellation of $10.0 million in Milestone Notes, reducing future obligations.
• Maintained a strong market position as a leader in ambulatory cardiac monitoring, delivering over 70% of Long-Term Continuous Monitoring (LTCM) services in the U.S. as of 2025.
• Extensive clinical evidence base with over 135 scientific research manuscripts supporting the iRhythm ACM Systems' effectiveness.
• Continued international expansion into the UK, selected European countries (Switzerland, Austria, Netherlands, Spain), and Japan.
• Management concluded that internal control over financial reporting was effective as of December 31, 2025.

Negatives

• Continued net losses, totaling $44.6 million in 2025, despite significant reduction from the prior year.
• Ongoing significant legal proceedings, including a securities class action, patent infringement lawsuits, and DOJ investigations, which incur substantial legal expenses and divert management attention.
• Increased operating expenses, particularly selling, general and administrative expenses, which rose by 18% to $492.6 million in 2025.
• Impairment charges of $4.5 million in 2025, including for internal-use software related to the Zio Watch, which will not be commercially launched.
• Higher contractual allowance reserves recognized in 2025 due to increased payer claims denials, impacting net revenue.
• Reliance on single-source vendors for critical components, posing potential supply chain risks.
• Uncertainty regarding future reimbursement rates and potential reductions by CMS or commercial payors.
• Risks associated with the evolving regulatory landscape for AI and medical devices, potentially leading to increased compliance costs or delays.
• The U.S. Preventive Services Task Force's (USPSTF) recommendation statement on Afib screening (January 2022) may deter some clinicians or payors from proactive screening.
• The Zio AT Customer Advisory Notice (September 2022) remains open in the public FDA recall database, despite the company's request for closure in March 2023.
• FDA warning letter (May 2023) and subsequent 483 observations (July 2024) indicate ongoing regulatory scrutiny and require significant remediation efforts.

Risks

• Reimbursement by Medicare is highly regulated and subject to change, with potential for discontinuation, recoupment, penalties, or exclusion from the program.
• Reduction or modification of reimbursement or other payments for iRhythm Services in the U.S. or international markets could adversely affect the business.
• Inability to expand contracts with third-party commercial payors or expand coverage for existing payors could impact commercial success.
• Reliance on iRhythm Services as the only current offerings; failure of these or future offerings to gain market acceptance would harm the business.
• Highly competitive market for remote cardiac monitoring solutions, with competitors potentially developing more effective devices or gaining greater market acceptance.
• Complex and highly regulated billing process, requiring substantial time and resources; failure to comply could lead to penalties and reputational harm.
• Audits or denials of claims by government agencies or payors could expose the company to recoupment, regulatory scrutiny, and penalties.
• Medical device developments (product enhancements, iterative changes, new technology, new indications) may trigger unpredictable regulatory reviews.
• Extensive compliance requirements for quality, design, safety, performance, and post-market surveillance of medical devices; non-compliance could trigger enforcement action, recalls, or judicial actions.
• High degree of medical and clinical input needed to evaluate complaints and adverse events, with potential disagreement over causality.
• International expansion exposes the company to market, regulatory, political, operational, financial, and economic risks.
• Risks associated with acquisitions of companies, products, and technologies, including integration difficulties and failure to realize anticipated benefits.
• Challenges and potential penalties from using third-party service providers or company resources located outside the U.S. for IDTF operations.
• Failure to comply with medical device, healthcare, and other governmental regulations could lead to substantial penalties.
• Changes in applicable laws or regulations or their interpretation/enforcement policies may require restructuring operations or adapting business strategies.
• Reliance on orders from licensed healthcare providers and strong relationships with them, subject to high scrutiny by government regulators.
• Communications with healthcare stakeholders are subject to high scrutiny for compliance, increasing risk of non-compliance allegations.
• Potential for material weaknesses in internal controls or failure to maintain an effective system, leading to misstatements or failure to meet reporting obligations.
• Significant fluctuations in financial results from quarter-to-quarter, not fully reflecting underlying business performance.
• Subject to legal proceedings and government investigations that could adversely affect business.
• Complex and evolving U.S. and foreign laws and regulations regarding privacy, data protection, and security, leading to claims, penalties, or increased costs.
• Stock price volatility influenced by research reports, market conditions, and other factors.
• Anti-takeover effects of charter documents and Delaware law could depress stock price.
• Indebtedness could adversely affect financial health and ability to respond to business changes.
• Servicing debt requires significant cash flow, which may not be sufficient.
• Capped call transactions may affect common stock value.
• Counterparty risk with respect to capped call transactions.
• Conversion of 2029 Notes will dilute ownership interest or depress stock price.
• Conditional conversion feature of 2029 Notes may adversely affect financial condition and operating results.
• Accounting method for convertible debt securities could materially affect reported financial results.
• Impact of domestic and global economic and political conditions, natural disasters, pandemics, and catastrophic events.
• Environmental, social, and corporate governance (ESG) regulations, policies, and provisions may complicate the supply chain and affect customer relationships.

Future Outlook

The company intends to continue expanding within the core ambulatory cardiac monitoring market, unlock market expansion through access, evidence, and AI, pursue international expansion, and extend the Zio platform into adjacent clinical opportunities such as obstructive sleep apnea, heart failure, and hypertension. It plans ongoing innovation in wearable biosensors, data analytics, reporting, and next-generation mobile cardiac telemetry solutions, including a pending Zio MCT device application to FDA.

Management Comments

• "Our mission is to boldly innovate to create trusted solutions that detect, predict, and prevent disease."
• "We believe iRhythm is uniquely positioned to address this opportunity through our scalable service model, long-term continuous monitoring capabilities, extensive clinical evidence base, and proprietary artificial intelligence."
• "As the market leader delivering more than 70% of LTCM services in the United States as of 2025, we believe our Zio platform is uniquely positioned to deliver this value as payers increasingly prioritize diagnostic accuracy and first-test resolution to reduce total cost of care."
• "We continue to focus on improving annual gross margins in the future, while navigating through the macroeconomic and supply chain headwinds discussed above that we expect to face."
• "Based on our board of directors and managements review of risks associated with cybersecurity threats, we have concluded that, to date, there have been no cybersecurity threats which have materially affected or are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition."

Industry Context

StockSavvy.ai notes that iRhythm operates in a competitive and rapidly evolving remote cardiac monitoring market, facing established players like Royal Philips (BioTelemetry), Boston Scientific (Preventice Solutions), and Baxter International (BardyDx, Welch Allyn), as well as tech giants like Apple and Fitbit entering the wearable ECG space. The company's focus on long-term continuous monitoring, AI-driven diagnostics, and expanding into primary care and population health aligns with broader industry trends towards early detection, value-based care, and digital health integration. The increasing prevalence of cardiac arrhythmias due to an aging population further underscores the market opportunity.

Comparison to Industry Standards

• The CAMELOT and AVALON studies, evaluating over 700,000 diagnostic-naive patients, demonstrated that iRhythm's LTCM Service (Zio) achieved the highest arrhythmia diagnostic yield, shortest time to diagnosis, and lowest total healthcare expenditures compared to other monitoring services.
• Holter monitors were 50% less likely, and event monitors 42% less likely, to detect a specified arrhythmia compared to Zio.
• LTCM competing devices were 1.4x to 4.3x more likely to require costly retesting compared to Zio.
• CAMELOT showed long-term continuous monitoring was associated with 180 fewer emergency department visits, 80 fewer inpatient hospitalizations, and 920 fewer outpatient visits per 1,000 patients compared to Holter.
• iRhythm is the market leader, delivering more than 70% of LTCM services in the United States as of 2025.

Corporate Governance

Legal Proceedings

• Securities class action lawsuit filed February 6, 2024, amended July 19, 2024, and October 7, 2024, alleging violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5. Motion to dismiss granted in part on June 3, 2025, dismissing individual defendants except CEO Quentin Blackford. Plaintiff filed motion to certify class action on November 3, 2025.
• Stockholder derivative actions filed in Delaware and Northern California, making similar allegations, stayed pending resolution of the securities class action.
• DOJ grand jury subpoenas received March 26, 2021, and September 13, 2021, requesting information related to FDA communications and products/services.
• DOJ Subpoena Duces Tecum received April 4, 2023, requesting documents regarding products and services.
• DOJ Petition for Order to Show Cause and Application for Enforcement filed July 1, 2024, regarding production of privileged documents. District Court ordered disclosure on May 30, 2025, which was appealed to the Ninth Circuit on July 17, 2025, and stayed. Reply brief due late February 2026.
• Civil investigative demand from DOJ's Civil Division's Commercial Litigation Branch received December 12, 2025, seeking information on Zio AT and reimbursement claims.
• Patent infringement lawsuit by Welch Allyn, Inc. filed February 20, 2024, amended April 24, 2024, February 14, 2025, and October 14, 2025, alleging infringement of patents by Zio devices. Company filed IPR petitions (denied), then Ex Parte Reexamination (instituted January 20, 2026).
• Patent infringement lawsuit by Bardy Diagnostics, Inc. filed December 10, 2024, amended December 26, 2024, and June 11, 2025, alleging infringement of patents by Zio monitor. Company filed counterclaims alleging infringement by BardyDx's Carnation Ambulatory Monitor.

Stakeholder Impact

• Shareholders: Potential dilution from convertible notes, stock price volatility, impact of legal proceedings, but also benefits from improved financial performance (revenue growth, reduced net loss, positive Adjusted EBITDA).
• Employees: Impact of workforce reorganizations, competitive compensation and benefits (401k, ESPP, wellness program), stock-based compensation, potential for disciplinary measures for insider trading violations.
• Customers (Healthcare Providers/Patients): Improved diagnostic tools (Zio monitor, Zio AT), enhanced patient experience, potential for new services (sleep apnea, heart failure), but also potential impact of reimbursement changes and service delays due to supply chain or operational issues.
• Suppliers: Reliance on single-source suppliers creates risk, potential for supply chain disruptions affecting component availability.
• Creditors: Impact of increased debt (2029 Notes), ability to service debt, counterparty risk with capped call transactions.
• Regulatory Authorities: Ongoing scrutiny from FDA and DOJ, compliance requirements for medical devices and billing practices, potential for enforcement actions.

Next Steps

• Continue to expand utilization within cardiology and electrophysiology practices and increase adoption across additional clinical specialties and settings, including primary care.
• Pursue proactive monitoring strategies focused on patients at risk for undiagnosed arrhythmias.
• Scale international markets deliberately over the medium to long term, focusing on embedding services into clinical practice and pursuing reimbursement pathways.
• Evaluate additional international market opportunities in the future.
• Selectively invest in opportunities to extend the core platform into adjacent clinical areas (obstructive sleep apnea, heart failure, hypertension).
• Continue ongoing innovation in wearable biosensors, data analytics, and reporting capabilities.
• Develop next-generation mobile cardiac telemetry solutions, including pursuing FDA clearance for the pending Zio MCT device.
• Continue to explore wearable solutions and patch-based sensors with additional parameters beyond ECG.
• Work with FDA to resolve issues outlined in the May 2023 warning letter and July 2024 483 observations.
• Complete contractual conditions with BioIS to cancel $10.0 million in Milestone Notes.
• Continue to defend privilege assertions in the DOJ legal proceeding.
• Continue to defend against patent infringement lawsuits by Welch Allyn and BardyDx.
• Continue to defend against the securities class action and derivative lawsuits.

Key Dates

Recommendation

iRhythm Holdings demonstrated strong operational improvements in 2025, with notable revenue growth and a shift to positive Adjusted EBITDA. This indicates solid market acceptance for its core cardiac monitoring services. However, the company faces a complex and extensive array of legal and regulatory challenges, including multiple ongoing lawsuits and government investigations, which could lead to significant costs, reputational damage, and operational disruptions. These uncertainties temper the positive financial performance, suggesting a 'hold' recommendation until there is greater clarity on the resolution of these material legal and regulatory risks.

Keywords

iRhythm Holdings, IRTC, digital healthcare, cardiac monitoring, ambulatory ECG, Zio monitor, Zio AT, arrhythmias, atrial fibrillation, FDA clearance, SEC filing, 10-K, financial results, revenue, net loss, Adjusted EBITDA, medical devices, corporate governance, risk management, intellectual property, legal proceedings, cybersecurity, convertible notes, BioIntelliSense, healthcare regulation, stock performance